Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Hepatitis

Free Subscription Articles published in J Med Virol Retrieve available abstracts of 83 articles: HTML format

Single Articles

March 2023
1. WU B, Tobe RG, Yan M, Lin H, et al
   Trends of Global Burden Related to HBV and HCV from 1990 to 2019: An Age-Period-Cohort Analysis.
   J Med Virol. 2023 Mar 11. doi: 10.1002/jmv.28663.
   PubMed     Abstract available
   
   
   
2. LIU Y, Chen M
   Is nonalcoholic fatty liver disease a predictor of treatment response in chronic hepatitis B?
   J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28654.
   PubMed     Abstract available
   
   
   
3. XU W, Zhu S, Yang L, Li Z, et al
   Safety and efficacy of double plasma molecular adsorption system with sequential low-volume plasma exchange in intermediate-stage hepatitis B virus-related acute-on-chronic liver failure.
   J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28650.
   PubMed     Abstract available
   
   
   
4. PISATURO M, Alessio L, Starace M, Macera M, et al
   CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
   J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
   PubMed     Abstract available
   
   
   
5. FENG Z, Huang P, Zhang J, Xia X, et al
   KIR2DL4/HLA-G polymorphisms were associated with HCV infection susceptibility among Chinese high-risk population.
   J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28645.
   PubMed     Abstract available
   
   
   
6. CHARRE C, Regue H, Deny P, Josset L, et al
   Improved Hepatitis Delta Virus genome characterization by single molecule full-length genome sequencing combined with VIRiONT pipeline.
   J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28634.
   PubMed     Abstract available
   
   
   
7. CAI T, Yue T, Xu M, Zhang P, et al
   Poor glycemic control in type-2 diabetic patients infected with hepatitis B: a retrospective propensity-matched study.
   J Med Virol. 2023 Mar 4. doi: 10.1002/jmv.28635.
   PubMed     Abstract available
   
   
   February 2023
8. TU W, Liu J, Qian F, Zhu L, et al
   Ubiquitin E3 ligase beta-TrCP negatively regulates surface protein of hepatitis B virus.
   J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28620.
   PubMed     Abstract available
   
   
   
9. LIAO H, Zhang H, Shao J, Li X, et al
   Nucleos(t)ide analogues altered quasispecies composition of hepatitis B virus (HBV)-resistant mutations in serum HBV DNA and serum HBV RNA.
   J Med Virol. 2023 Feb 25. doi: 10.1002/jmv.28612.
   PubMed     Abstract available
   
   
   
10. KASHYAP N, Islam M, Kaur H, Tiwari D, et al
    Oxidative stress - a key determinant of complications and negative outcome in Hepatitis E virus infected pregnancies: a comprehensive account involving cases from northeast India.
    J Med Virol. 2023 Feb 13. doi: 10.1002/jmv.28576.
    PubMed     Abstract available
    
    
    
11. SHUI LP, Zhu Y, Duan XQ, Chen YT, et al
    HBsAg (-)/HBsAb (-)/HBeAg (-)/HBeAb (+)/HBcAb (+) predicts a high risk of hepatitis B reactivation in patients with B-cell lymphoma receiving rituximab based immunochemotherapy.
    J Med Virol. 2023 Feb 3. doi: 10.1002/jmv.28549.
    PubMed     Abstract available
    
    
    
12. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed     Abstract available
    
    
    
13. CHEN S, Wang B, Zhou J, Wu X, et al
    A new glutamine synthetase index to evaluate hepatic lobular restoration in advanced fibrosis during anti-HBV therapy.
    J Med Virol. 2023;95:e28555.
    PubMed     Abstract available
    
    
    January 2023
14. XIE J, Ding Y, Li X, Pu R, et al
    Association of ESR1 gene polymorphisms with the susceptibility to Hepatitis B virus infection and the clinical outcomes.
    J Med Virol. 2023 Jan 20. doi: 10.1002/jmv.28510.
    PubMed     Abstract available
    
    
    
15. HASSEBROEK AM, Sooryanarain H, Lynn Heffron C, Hawks SA, et al
    A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28503.
    PubMed     Abstract available
    
    
    
16. TANG Y, Fan R, Lan Z, Xie Q, et al
    Impact of nonalcoholic fatty liver disease status change on antiviral efficacy of nucleos(t)ide analogues in HBeAg-positive chronic hepatitis B.
    J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28501.
    PubMed     Abstract available
    
    
    
17. SUDA G, Baba M, Yamamoto Y, Sho T, et al
    Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitis.
    J Med Virol. 2023 Jan 4. doi: 10.1002/jmv.28452.
    PubMed     Abstract available
    
    
    
18. XIANG Z, Jiang C, Yang J, Huang L, et al
    Serum extracellular vesicle-derived ASS1 is a promising predictor for the occurrence of HEV-ALF.
    J Med Virol. 2023;95:e28425.
    PubMed     Abstract available
    
    
    
19. MOHAMED AA, Esmail OE, Ibrahim AMA, Makled S, et al
    The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients.
    J Med Virol. 2023;95:e28343.
    PubMed     Abstract available
    
    
    December 2022
20. KAR A, Samanta A, Mukherjee S, Barik S, et al
    The HBV web: An insight into molecular interactomes between the Hepatitis B virus and its host en route to hepatocellular carcinoma.
    J Med Virol. 2022 Dec 27. doi: 10.1002/jmv.28436.
    PubMed     Abstract available
    
    
    
21. TUNCEL B, Kaygusuz S, Sayin Kocakap DB, Aksoy E, et al
    DO CCR5 (CCR5Delta32) AND TLR3 (RS5743313) GENE POLYMOPHISMS PREVENT CHRONIC HEPATITIS B INFECTION?
    J Med Virol. 2022 Dec 7. doi: 10.1002/jmv.28376.
    PubMed     Abstract available
    
    
    November 2022
22. ARANDHARA VL, Patrick McClure C, Tarr AW, Chappell S, et al
    SCAVENGER RECEPTOR CLASS B TYPE I GENETIC VARIANTS ASSOCIATED WITH DISEASE SEVERITY IN CHRONIC HEPATITIS C VIRUS INFECTION.
    J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28331.
    PubMed     Abstract available
    
    
    
23. CHEN J, Li F, Tian J, Xie X, et al
    Varicella Zoster Virus Reactivation Following COVID-19 Vaccination in patients with autoimmune inflammatory rheumatic diseases: A cross-sectional Chinese study of 318 cases.
    J Med Virol. 2022 Nov 13. doi: 10.1002/jmv.28307.
    PubMed     Abstract available
    
    
    
24. SHI Y, Jin X, Wu S, Liu J, et al
    Release of hepatitis B virions is positively regulated by glucose-regulated protein 78 through direct interaction with preS1.
    J Med Virol. 2022 Nov 2. doi: 10.1002/jmv.28271.
    PubMed     Abstract available
    
    
    October 2022
25. LUCIANI L, Bichon A, Mortier C, Bourenne J, et al
    Acute hepatitis associated with an echovirus 9 infection in a heart transplant recipient.
    J Med Virol. 2022 Oct 30. doi: 10.1002/jmv.28262.
    PubMed     Abstract available
    
    
    
26. CHEN J, Yu S, Lang Z, Jin Y, et al
    Development and validation of a potential biomarker to improve the assessment of liver fibrosis progression in patients with chronic hepatitis B.
    J Med Virol. 2022 Oct 18. doi: 10.1002/jmv.28239.
    PubMed     Abstract available
    
    
    
27. KANEKO S, Kurosaki M, Mashiba T, Marusawa H, et al
    Risk factors for hepatocellular carcinoma at baseline and 1 year after initiation of nucleos(t)ide analog therapy for chronic hepatitis B.
    J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28210.
    PubMed     Abstract available
    
    
    
28. ZHANG F, Yang Z, Dai C, He Q, et al
    Efficacy of an accelerated vaccination schedule against hepatitis E virus infection in pregnant rabbits.
    J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28193.
    PubMed     Abstract available
    
    
    September 2022
29. LUO J, Liang X, Xin J, Li P, et al
    Serum ferritin diagnosis and prediction of hepatitis B virus-related acute-on-chronic liver failure.
    J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28183.
    PubMed     Abstract available
    
    
    
30. ADEBOYEJO K, King B, Tsoleridis T, Tarr A, et al
    Hepatitis C subtyping assay failure in UK patients born in Sub-Saharan Africa: implications for global treatment and elimination.
    J Med Virol. 2022 Sep 27. doi: 10.1002/jmv.28178.
    PubMed     Abstract available
    
    
    
31. YU X, Zheng Y, Zeng D, Zhou Y, et al
    Decreased frequency of a novel T-lymphocyte subset, CD3(+) CD4(-) CD7(+) CD57(-) T cells, in hepatitis B virus-related end-stage liver disease might contribute to disease progression.
    J Med Virol. 2022 Sep 6. doi: 10.1002/jmv.28129.
    PubMed     Abstract available
    
    
    
32. CHALID MT, Turyadi, Ie SI, Sjahril R, et al
    A cautionary note to hepatitis B e antigen (HBeAg)-negative test results in pregnant women in an area prevalent of HBeAg-negative chronic hepatitis B.
    J Med Virol. 2022 Sep 5. doi: 10.1002/jmv.28125.
    PubMed     Abstract available
    
    
    August 2022
33. PRICE AS, Nelson AK, Ghosh A, Kottilil S, et al
    A Phase 2 Open Label Study of Ledipasvir/Sofosbuvir for 12 Weeks in Subjects with Hepatitis B Virus Infection.
    J Med Virol. 2022 Aug 31. doi: 10.1002/jmv.28105.
    PubMed     Abstract available
    
    
    
34. CHEN Z, Yuan Y, Yang D, Luo M, et al
    Antiviral activities of Polygonum Perfoliatum L. extract and related phenolic acid constituents against hepatitis B virus.
    J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28087.
    PubMed     Abstract available
    
    
    
35. MIYAZAWA D
    Potential mechanisms by which adeno-associated virus type 2 causes unexplained hepatitis in children.
    J Med Virol. 2022 Aug 22. doi: 10.1002/jmv.28082.
    PubMed     Abstract available
    
    
    
36. SARFARAZ N, Somarowthu S, Bouchard MJ
    The Interplay of Long Non-Coding RNAs and Hepatitis B Virus.
    J Med Virol. 2022 Aug 9. doi: 10.1002/jmv.28058.
    PubMed     Abstract available
    
    
    July 2022
37. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
    Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
    J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
    PubMed     Abstract available
    
    
    
38. CHEEMA HA, Shahid A, Aziz H
    Severe acute pediatric hepatitis: the undue emphasis on adenovirus needs to be reassessed.
    J Med Virol. 2022 Jul 20. doi: 10.1002/jmv.28014.
    PubMed     Abstract available
    
    
    
39. LIAN J, Kuang W, Jia H, Lu Y, et al
    Pegylated interferon-alpha-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for naive HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomize
    J Med Virol. 2022 Jul 14. doi: 10.1002/jmv.28003.
    PubMed     Abstract available
    
    
    
40. ZHANG Q, Liang J, Yin J, Jiang Y, et al
    Real-life impact of tenofovir disoproxil fumarate and entecavir therapy on lipid profile, glucose and uric acid in chronic hepatitis B patients.
    J Med Virol. 2022 Jul 6. doi: 10.1002/jmv.27977.
    PubMed     Abstract available
    
    
    
41. RATHO RK, Thakur V, Arya S, Singh MP, et al
    Placenta as a site of HEV replication and inflammatory cytokines modulating the immunopathogenesis of HEV in pregnant women.
    J Med Virol. 2022;94:3457-3463.
    PubMed     Abstract available
    
    
    June 2022
42. ZHONG S, Liu Z, Zhou Y, Zhang T, et al
    Longitudinal mapping of hepatitis B vaccine-induced B-cell linear epitopes in healthy individuals.
    J Med Virol. 2022 Jun 8. doi: 10.1002/jmv.27926.
    PubMed     Abstract available
    
    
    
43. ZHENG XQ, Li X, Liu J, Shi L, et al
    Horizontal transmission might be a common route of hepatitis B virus exposure in highly endemic areas.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27905.
    PubMed     Abstract available
    
    
    
44. OHTA A, Ogawa E, Murata M, Matsumoto Y, et al
    Impact of the PNPLA3 genotype on the risk of hepatocellular carcinoma after hepatitis C virus eradication.
    J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27904.
    PubMed     Abstract available
    
    
    May 2022
45. QI X, Li F, Zhang Y, Zhu H, et al
    STAT4 genetic polymorphism significantly affected HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients receiving Peginterferon-alpha therapy: A prospective cohort study in China Running title: STAT4 variation affecting response to PegIF
    J Med Virol. 2022 May 24. doi: 10.1002/jmv.27880.
    PubMed     Abstract available
    
    
    
46. ZENG QL, Yu ZJ, Lv J, Zhang HX, et al
    Sofosbuvir-based Therapy for Late Pregnant Women and Infant with Severe Chronic Hepatitis C: A Case Series Study.
    J Med Virol. 2022 May 20. doi: 10.1002/jmv.27877.
    PubMed     Abstract available
    
    
    
47. LIANG LY, Yip TC, Lai JC, Lam AS, et al
    Tenofovir alafenamide is associated with improved alanine aminotransferase and renal safety compared to tenofovir disoproxil fumarate.
    J Med Virol. 2022 May 17. doi: 10.1002/jmv.27863.
    PubMed     Abstract available
    
    
    
48. HAKIM MS
    The recent outbreak of acute and severe hepatitis of unknown etiology in children: a possible role of human adenovirus infection?
    J Med Virol. 2022 May 16. doi: 10.1002/jmv.27856.
    PubMed     Abstract available
    
    
    
49. XIE Z, Deng K, Xia Y, Zhang C, et al
    Efficacy and safety of direct-acting antiviral therapies and baseline predictors for treatment outcomes in hepatitis C patients: a multi-center, real-world study in Guangdong, China.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27851.
    PubMed     Abstract available
    
    
    
50. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
    Human Herpesvirus 8 seroprevalence among blood donors in Mali.
    J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
    PubMed     Abstract available
    
    
    
51. KOC OM, van Oorschot E, Brandts L, Lashof AO, et al
    Timing of primary three dose hepatitis B vaccination and postvaccination serologic testing among a large cohort of healthy adults.
    J Med Virol. 2022 May 10. doi: 10.1002/jmv.27848.
    PubMed     Abstract available
    
    
    April 2022
52. KHAN YH, Mallhi TH, Alanazi AS, Butt MH, et al
    Outbreak of Acute Hepatitis of Unknown etiology in Children; The Critical Role of Healthcare Professionals in Neutralizing Misleading Narratives during the COVID-19 Pandemic.
    J Med Virol. 2022 Apr 29. doi: 10.1002/jmv.27819.
    PubMed    
    
    
    
53. ZHANG C, Liu Y, Li J, Liu H, et al
    Dose-response relationship between qAnti-HBc and liver inflammation in chronic hepatitis B with normal or mildly elevated ALT based on liver biopsy.
    J Med Virol. 2022 Apr 13. doi: 10.1002/jmv.27779.
    PubMed     Abstract available
    
    
    
54. ZHAO D, Yu S, Guo P, Zhang X, et al
    Identification of potential plasma markers for hepatitis B virus-related chronic hepatitis and liver fibrosis/cirrhosis.
    J Med Virol. 2022 Apr 5. doi: 10.1002/jmv.27761.
    PubMed     Abstract available
    
    
    March 2022
55. LIN P, Wen DY, Pang JS, Liao W, et al
    Proteomics profiling of nontumor liver tissues identifies prognostic biomarkers in hepatitis B-related hepatocellular carcinoma.
    J Med Virol. 2022 Mar 21. doi: 10.1002/jmv.27732.
    PubMed     Abstract available
    
    
    
56. YU J, Shi X, Yu H, Wu J, et al
    Impact of hepatitis-B-surface-antigen-positive grafts on liver transplantation in patients with benign and malignant liver disease.
    J Med Virol. 2022 Mar 7. doi: 10.1002/jmv.27703.
    PubMed     Abstract available
    
    
    February 2022
57. WU J, Xu Y, Cui Y, Bortolanza M, et al
    Dynamic changes of serum metabolites associated with infection and severity of patients with acute hepatitis E infection.
    J Med Virol. 2022 Feb 23. doi: 10.1002/jmv.27669.
    PubMed     Abstract available
    
    
    
58. JACKSON K, Holgate T, Tekoaua R, Nicholson S, et al
    Evaluation of dried blood spots for hepatitis B and D serology and nucleic acid testing.
    J Med Virol. 2022;94:642-648.
    PubMed     Abstract available
    
    
    January 2022
59. MOREIRA LVL, Malheiros AP, Barbosa KMV, Freitas PEB, et al
    The first evidence of Hepatitis A virus subgenotype IIIA in the Eastern Brazilian Amazon, 1982-1983.
    J Med Virol. 2022 Jan 25. doi: 10.1002/jmv.27625.
    PubMed     Abstract available
    
    
    
60. LUO M, Chen Z, Liu M, Liang Q, et al
    Inhibitory Activities of Ranunculus japonicus Thunb. Ethanol Extract against Hepatitis B Virus.
    J Med Virol. 2022 Jan 24. doi: 10.1002/jmv.27621.
    PubMed     Abstract available
    
    
    
61. LEON FJF, Silva LLD, Santos AC, Duarte da Costa V, et al
    Immunological and virological aspects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and hepatitis C virus.
    J Med Virol. 2022 Jan 22. doi: 10.1002/jmv.27614.
    PubMed     Abstract available
    
    
    
62. YU K, Mei Y, Wang Z, Liu B, et al
    LncRNA LINC00924 upregulates NDRG2 to inhibit epithelial-mesenchymal transition via sponging miR-6755-5p in hepatitis B virus-related hepatocellular carcinoma.
    J Med Virol. 2022 Jan 8. doi: 10.1002/jmv.27578.
    PubMed     Abstract available
    
    
    December 2021
63. XIE Y, Ma H, Feng B, Song G, et al
    Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase.
    J Med Virol. 2021 Dec 24. doi: 10.1002/jmv.27545.
    PubMed     Abstract available
    
    
    
64. DENG H, Feng Q, Wu Y, Lin H, et al
    Immune response to hepatitis B vaccination in human immunodeficiency virus-positive patients in China: A 2-year retrospective study.
    J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27523.
    PubMed     Abstract available
    
    
    November 2021
65. BOLINA-SANTOS E, Chaves DG, da Silva-Malta MCF, Carmo RA, et al
    HCV infection in hemophilia A patients is associated with altered cytokines and chemokines profile and might modulate the levels of FVIII inhibitor.
    J Med Virol. 2021 Nov 5. doi: 10.1002/jmv.27432.
    PubMed     Abstract available
    
    
    
66. ZHENG S, Li M, Pan X, Huang X, et al
    Association of IL-32 rs28372698 polymorphism with active chronic HBV infection.
    J Med Virol. 2021;93:6236-6240.
    PubMed     Abstract available
    
    
    October 2021
67. JI Q, Chu X, Zhou Y, Liu X, et al
    Safety and efficacy of grazoprevir/elbasvir in the treatment of acute hepatitis C in hemodialysis patients.
    J Med Virol. 2021 Oct 2. doi: 10.1002/jmv.27374.
    PubMed     Abstract available
    
    
    September 2021
68. WU J, Bortolanza M, Zhai G, Shang A, et al
    Gut Microbiota Dysbiosis Associated with Plasma Levels of Interferon-gamma and Viral Load in Patients with Acute Hepatitis E Infection.
    J Med Virol. 2021 Sep 22. doi: 10.1002/jmv.27356.
    PubMed     Abstract available
    
    
    
69. KAZMI SK, Khan FMA, Natoli V, Hunain R, et al
    Viral hepatitis amidst COVID-19 in Africa: Implications and Recommendations.
    J Med Virol. 2021 Sep 10. doi: 10.1002/jmv.27330.
    PubMed     Abstract available
    
    
    
70. NICOLINI LA, Menzaghi B, Molteni C, Vichi F, et al
    Comments on "Real-world re-treatment outcomes of direct-acting antiviral therapy failure in patients with chronic hepatitis C".
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27329.
    PubMed    
    
    
    
71. YAO K, Wang J, Wang L, Xia J, et al
    Association of anti-HBc and liver inflammation in HBeAg-negative chronic hepatitis B virus infected patients with normal ALT and detectable HBV DNA.
    J Med Virol. 2021 Sep 9. doi: 10.1002/jmv.27327.
    PubMed     Abstract available
    
    
    August 2021
72. TARAFDAR S, Virata ML, Yan H, Zhong L, et al
    Multiple Epitopes of Hepatitis B Virus Surface Antigen Targeted by Human Plasma-derived Immunoglobulins Coincide with Clinically Observed Escape Mutations.
    J Med Virol. 2021 Aug 18. doi: 10.1002/jmv.27278.
    PubMed     Abstract available
    
    
    
73. YAO Y, Shen Y, Shao H, Liu Y, et al
    Polymorphisms of RIG-I-like receptor influence HBV clearance in Chinese Han population.
    J Med Virol. 2021;93:4957-4965.
    PubMed     Abstract available
    
    
    July 2021
74. WEI MT, Le MH, Landis C, Trinh H, et al
    Evaluation of ethnic influence in the application of a hepatocellular carcinoma predictive model for chronic hepatitis C.
    J Med Virol. 2021 Jul 5. doi: 10.1002/jmv.27168.
    PubMed     Abstract available
    
    
    June 2021
75. LEUMI S, El Kassas M, Zhong J
    Hepatitis C virus-genotype 4: a poorly characterized endemic genotype.
    J Med Virol. 2021 Jun 29. doi: 10.1002/jmv.27165.
    PubMed     Abstract available
    
    
    
76. TADA T, Kurosaki M, Nakamura S, Hasebe C, et al
    Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
    J Med Virol. 2021 Jun 25. doi: 10.1002/jmv.27157.
    PubMed     Abstract available
    
    
    
77. JI H, Chen S, He Q, Wang W, et al
    The different replication between nonenveloped and quasi-enveloped hepatitis E virus.
    J Med Virol. 2021 Jun 2. doi: 10.1002/jmv.27121.
    PubMed     Abstract available
    
    
    
78. WANG Y, Li X, Chen Q, Jiao F, et al
    The relationship between liver pathological inflammation degree and pyroptosis in chronic hepatitis B patients.
    J Med Virol. 2021 Jun 1. doi: 10.1002/jmv.27114.
    PubMed     Abstract available
    
    
    
79. SAJJAD M, Ali S, Baig S, Sharafat S, et al
    HBV S antigen evolution in the backdrop of HDV infection affects epitope processing and presentation.
    J Med Virol. 2021;93:3714-3729.
    PubMed     Abstract available
    
    
    
80. JACKSON K, Tekoaua R, Li X, Locarnini S, et al
    Real-world application of the Xpert(R) HBV viral load assay on serum and dried blood spots.
    J Med Virol. 2021;93:3707-3713.
    PubMed     Abstract available
    
    
    April 2021
81. XU Z, Lin JZ, Zeng YF, Yang XH, et al
    Changes of cytokine levels and T cell surface molecules in patients with chronic hepatitis B and the association with functional cure.
    J Med Virol. 2021 Apr 29. doi: 10.1002/jmv.27041.
    PubMed     Abstract available
    
    
    
82. BULFONI M, Pravisani R, Dalla E, Cesselli D, et al
    miRNA expression profiles in liver grafts of HCV and HIV/HCV infected recipients, six months after liver transplantation.
    J Med Virol. 2021 Apr 5. doi: 10.1002/jmv.26999.
    PubMed     Abstract available
    
    
    April 2019
83. EL KASSAS M, Alboraie M, Omar H, El Latif YA, et al
    High success rates for the use of ombitasvir/paritaprevir/ritonavir containing regimens in treatment of naive and experienced chronic hepatitis C genotype 4: Real world results.
    J Med Virol. 2019 Apr 5. doi: 10.1002/jmv.25478.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Hepatitis is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: